17 October 2024 The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM) is set to grow from $11.5 billion in 2023 to $30.8 billion in 2033, driven by the launch of the first biologic for COPD and other pioneering pipeline agents.
As the European Parliament prepares for the confirmation hearings of the new Commissioners, the Open Trade Coalition is reiterating its call for a bold and open EU trade policy, according to a posting on the European Federation of Pharmaceutical Industries and Associations (EFPIA) website. 18 October 2024
After a couple of negative decisions, the US Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). 18 October 2024
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Having been retained on the US Trade Representative's (USTR's) Priority Watch List alongside six other countries, the Indian government has undertaken an intellectual property review exercise to assess the risks to innovation and economic growth as posed by the USTR, reports The Pharma Letter’s India correspondent. 1 August 2022
The US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Zoryve (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. 30 July 2022
HIV specialist company ViiV Healthcare today announced week 240 results from the Phase III BRIGHTE study of Rukobia (fostemsavir) in heavily treatment-experienced (HTE) adults with multidrug-resistant HIV-1 infection who have very few treatment options left available to them due to resistance, intolerance, or other safety concerns. 29 July 2022
Danish diabetes care giant Novo Nordisk (NOV: N) today announced headline results from the ONWARDS 3 and ONWARDS 4 Phase IIIa trials with once-weekly insulin icodec in adults with type 2 diabetes. 29 July 2022
US pharma major AbbVie’s shares were up 1.5% at $147.50 pre-market, as it announced financial results for the second quarter ended June 30, 2022. 29 July 2022
Anglo-Swedish drugmaker AstraZeneca was trading nearly 1% lower in London trading early on Friday afternoon after presenting its latest financial results. 29 July 2022
Shares of Canada-based Bausch Health Companies tumbled more than 50% yesterday following an adverse US court ruling in a patent dispute over one of the company’s key drugs. 29 July 2022
US pharma company Acer Therapeutics and its Switzerland-based collaboration partner Relief Therapeutics are confident that their New Drug Application (NDA) for ACER-001 (sodium phenylbutyrate) is back on track. 29 July 2022
US pharma giant Merck & Co recorded second-quarter sales of $14.6 billion, a rise of 28% on the same period in 2021 and well above the FactSet consensus of $13.87 billion. 28 July 2022
Consultancy Vital Transformation has published new research showing that the Build Back Better Act (BBBA) will have a negative impact on patient access to new therapies as funding would be severely curtailed for R&D. 28 July 2022
Japanese pharma giant Takeda today announced strong financial results for the first quarter of fiscal year 2022 (period ended June 30, 2022) and is on track to meet its full-year management guidance. 28 July 2022
Belgium’s largest pharma company UCB this morning posted financial results for the first half of 2022, which it described as “strong,” but investors were not convinced, sending the firm’s shares more than 4% lower to 77.92 euros. 28 July 2022
Shares of Switzerland-based ObsEva fell as much as 80% yesterday, after the women’s health therapy developer revealed it has hit a stumbling block in the US approval of its linzagolix for uterine fibroids. 28 July 2022
Cidara Therapeutics’ shares closed up 11.6% at $0.76 yesterday, when it announced that it has entered into a license agreement with Melinta Therapeutics under which Cidara has granted Melinta an exclusive license to commercialize rezafungin in the USA. 28 July 2022
UK pharma major GSK has presented its first set of financial results since it spun off its consumer health division Haleon earlier this month. 27 July 2022
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.